ResMed vs Teleflex
RMD and TFX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RMD and TFX compare
ResMed is the larger company, worth 4.9 times as much as Teleflex ($33.5B against $6.8B).
Teleflex grew revenue faster over the last twelve months (30.7% versus 9.0% for ResMed).
ResMed keeps more of each dollar of sales as profit, with a net margin of 27.8% compared with −45.8% at Teleflex.
Both pay dividends: ResMed yields 0.78% and Teleflex 0.64%.
ResMed scores higher on the StockData Score (21 against 7 for Teleflex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RMD | TFX |
|---|---|---|
| Size and price | ||
| Market cap | $33.5B | $6.8B |
| Share price | $237.85 | $159.55 |
| Change, 1 year | −2.7% | 49.1% |
| Change, 5 years | −5.3% | −47.7% |
| Beta (5Y) | 0.31 | 0.35 |
| Employees | 11K | 16K |
| StockData Score | ||
| Total score | 21 (better) | 7 |
| Valuation score | 4 (better) | 1 |
| Growth score | 3 (better) | 1 |
| Performance score | 6 (better) | 1 |
| Health score | 4 (better) | 1 |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | 21.7× | – |
| P/S | 5.8× | 3.0× (better) |
| P/B | 5.6× | 2.3× (better) |
| EV/EBITDA | 15.6× (better) | 48.1× |
| P/FCF | 20.8× (better) | 40.1× |
| PEG | 1.10 | – |
| FCF yield | 4.8% (better) | 2.5% |
| Fair value | $276.76 | $37.56 |
| Margin of safety | 14.1% (better) | −325% |
| Growth | ||
| Revenue growth (TTM) | 9.0% | 30.7% (better) |
| Revenue growth, 5Y average | 12.1% (better) | −4.7% |
| Net income growth (TTM) | 10.8% (better) | −638% |
| EPS growth (TTM) | 12.4% (better) | −645% |
| EPS growth, 5Y average | 26.3% | – |
| Profitability | ||
| Gross margin | 61.1% (better) | 54.9% |
| Operating margin | 33.0% (better) | 2.0% |
| Net margin | 27.8% (better) | −45.8% |
| FCF margin | 28.1% (better) | 7.5% |
| Return on equity | 26.4% (better) | −28.9% |
| Return on invested capital | 29.7% (better) | 0.62% |
| Financial health | ||
| Debt / equity | 0.03 (better) | 0.97 |
| Net debt / EBITDA | −0.41 | 13.01 (better) |
| Interest coverage | – | 0.4× |
| Current ratio | 2.65 (better) | 2.60 |
| Altman Z-score | 11.94 (better) | 1.60 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.78% (better) | 0.64% |
| Payout ratio | 22.4% | – |
| Years of dividend growth | 5 (better) | 0 |
| Dividend growth, 5Y average | 9.0% (better) | 0.00% |
| Buyback yield | 4.2% (better) | 3.7% |
| Shareholder yield | 5.0% (better) | 4.3% |
| Ownership | ||
| Held by institutions | 71.1% | 113% |
| Held by insiders | 1.3% | 0.73% |
| Insider net buying, 12 months | −$19.6M | – |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | – | 9.7% |
Go deeper
- RMD stock overview
- RMD income statement
- RMD valuation and score
- TFX stock overview
- TFX income statement
- TFX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.